Build status - In Progress

A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once daily for the Treatment of HIV-1 Infection in subjects Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study

Recruiting
99 years or below
All
1 Location

Brief description of study

This trial is testing doravirine/islatravir (also known as MK-8591A or DOR/ISL) in people living with HIV-1 who have participated in another Merck-sponsored trial of DOR/ISL. The main purpose of this trial is to test the safety and efficacy of DOR/ISL and give patients continued access to DOR/ISL through this rollover study. Participants will take DOR/ISL for an additional 48 weeks or until DOR/ISL is commercially available and come in for routine study visits every 3 months.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 10 May 2023. Study ID: 851182

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center